Sponsor or institution
Clinical trials and research at Jiangsu Hansoh Pharmaceutical Co., Ltd.
As of November 12, 2026, Find a Trial lists 17 clinical trials run by Jiangsu Hansoh Pharmaceutical Co., Ltd. that are recruiting, at sites in 4 countries (most in China (16), Bosnia and Herzegovina (1), Bulgaria (1)). By phase: Phase 1 (11), Phase 1/2 (3), Phase 3 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 17Clinical trials
- 4Countries
Newest trials
All recruiting trials (17)
-
How HS-10506 behaves in people with moderate liver problems compared to healthy individuals
This study tests a single 20 mg dose of HS-10506 to see how people with moderate hepatic impairment process the drug compared with people with normal liver function.
-
HS-10504 vs platinum-based chemotherapy in EGFR C797S+ NSCLC
This study tests whether the oral drug HS-10504 can help adults with advanced NSCLC that has the EGFR C797S mutation after prior EGFR therapy, by comparing it to standard platinum-based chemotherapy.
-
Oral HS-10542 for paroxysmal nocturnal hemoglobinuria
This study will test whether the oral drug HS-10542 can reduce hemolysis and raise hemoglobin in adults with PNH, including those not fully helped by C5 inhibitor therapy.
-
HS-10566 treatment in high-risk non-muscle-invasive bladder cancer where surgery isn’t an option
This study tests HS-10566 to see if it can help people with high-risk NMIBC who can’t or won’t have radical cystectomy.
-
Aumolertinib for European adults with EGFR‑mutant advanced non‑small cell lung cancer
This Phase 1 trial tests daily oral aumolertinib in European adults with advanced or metastatic NSCLC that has activating EGFR mutations to see how the drug is processed in the body and whether it is safe and tolerable.
-
HS-10516 plus lenvatinib for advanced clear-cell kidney cancer
This study will test whether adding HS-10516 to lenvatinib helps adults with advanced clear-cell kidney cancer who have progressed after at least one prior systemic treatment.
-
HS-20094 pen treatment for adults with overweight or obesity
This test will see if two HS-20094 pen devices deliver the medication the same way in adults who are overweight or obese.
-
HS-10542 in healthy adults
This study tests how the oral drug HS-10542 is tolerated and processed in healthy adults and whether eating affects its blood levels.
-
HS-20118 safety, how the body handles it, and food effects in healthy people and those with plaque psoriasis
This trial will test whether oral HS-20118 is safe and how the body processes it in healthy adults and in people with moderate to severe plaque psoriasis, including whether food changes absorption.
-
Evaluating Aumolertinib's Effect on Midazolam in Lung Cancer Patients
This study is testing how a new lung cancer drug, aumolertinib, affects the way the body processes another medication, midazolam, in patients with advanced non-small cell lung cancer who have specific genetic changes.
-
HS-10502 combination treatment for advanced solid tumors
This study will test whether the oral drug HS-10502, given with other cancer medicines, is safe and can help people with advanced solid tumors such as recurrent ovarian cancer, HER2‑negative or triple‑negative breast cancer, and advanced prostate cancer.
-
Testing HS-10516 for tumors related to VHL Syndrome
This study is testing a new medication called HS-10516 to see if it can help Chinese patients with tumors related to Von Hippel-Lindau Syndrome feel better and improve their treatment options.
-
HS-10504 for advanced or metastatic non-small-cell lung cancer
This Phase 1 trial tests HS-10504, a fourth-generation EGFR inhibitor, in adults with advanced or metastatic EGFR-positive NSCLC who have progressed after prior EGFR-TKI therapy.
-
Testing HS-10365 for advanced lung cancer with RET gene fusion
This study is testing a new pill called HS-10365 to see if it helps people with advanced lung cancer that has a specific gene change and who haven't had treatment before.
-
Testing HS-10386 for advanced solid tumors
This study is testing a new drug called HS-10386 to see if it can help people with advanced solid tumors that haven't responded to other treatments.
-
Testing HS-10502 for advanced solid tumors
This study is testing a new drug called HS-10502 to see if it can help people with advanced solid tumors that have certain genetic mutations and who haven't had success with standard treatments.
-
Assessing Almonertinib after Chemoradiation in Stage III Non-small Cell Lung Cancer
This study is testing if a new drug called Almonertinib can help people with stage III non-small cell lung cancer feel better after they have received chemoradiation.
Quick answers
How many clinical trials run by Jiangsu Hansoh Pharmaceutical Co., Ltd. are recruiting right now?
17, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in China (16 trials), Bosnia and Herzegovina (1 trial), Bulgaria (1 trial), Moldova (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 11, Phase 1/2: 3, Phase 3: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.